NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced the launch of its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, the company's proprietary cannabinoid-based drug candidate, for the treatment of Tourette Syndrome (TS) in adults.
The initiation of the Yale site marks a pivotal expansion of the trial, which is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel. SCI-110 is a novel combination of dronabinol and palmitoylethanolamide, designed to reduce tics and associated comorbid symptoms while aiming to minimize side effects. This innovative dosage form leverages the endocannabinoid system to potentially offer a more effective and safer alternative to current therapies.
Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera, emphasized the significance of this milestone: “Launching a U.S. site at the Yale Child Study Center represents a significant milestone in our global development program for SCI-110. TS remains a major unmet medical need with limited therapeutic options, particularly in adults who continue to experience persistent, severe, and often debilitating symptoms. We believe SCI-110 has the potential to introduce a novel, more effective and safer treatment approach.”
The Phase IIb trial is a randomized, double-blind, placebo-controlled, cross-over study designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110 in patients aged 18-65. The primary endpoint is the change in tic severity measured by the Yale Global Tic Severity Scale (YGTSS) at weeks 12 and 26 compared to baseline. This follows the positive results from the Phase IIa study, which demonstrated an average tic reduction of 21% across the entire participant sample, as measured by the gold-standard YGTSS Total Tic Score.
The implications of this trial are profound. Tourette Syndrome affects approximately 1 in 100 individuals, yet treatment options remain scarce, especially for adults with severe symptoms. Current medications often come with significant side effects, and behavioral therapies are not universally accessible. If SCI-110 proves effective in this larger Phase IIb study, it could become the first cannabinoid-based treatment specifically approved for TS, offering new hope to patients who have exhausted existing options.
Moreover, the collaboration with the Yale Child Study Center, a world-renowned institution for neuropsychiatric research, lends credibility and expertise to the trial. Dr. Bloch is a leading researcher in the field, and his involvement ensures rigorous scientific standards. The global nature of the trial—spanning North America, Europe, and the Middle East—also enhances the generalizability of the results, potentially accelerating regulatory approval in multiple jurisdictions.
For NeuroThera Labs, this trial is a critical step toward advancing its pipeline and establishing a foothold in the central nervous system (CNS) therapeutic area. The company's focus on innovative combinations of existing compounds aims to address unmet needs in conditions like TS, where the pathophysiology is complex and current treatments are inadequate.
Investors and stakeholders will be closely monitoring the trial's progress, as successful outcomes could significantly impact the company's valuation and the broader landscape of TS management. The announcement also underscores the growing interest in cannabinoid-based therapies for neurological disorders, a trend that may reshape treatment paradigms in the coming years.
While the road to regulatory approval is long, the initiation of this Phase IIb trial at a prestigious U.S. institution marks a tangible step forward. The data generated will be crucial in determining whether SCI-110 can fulfill its promise as a safer and more effective treatment for Tourette Syndrome, potentially improving the lives of millions worldwide.
